HEALTH

Why Testing Gonorrhea for Drug Resistance May Pay Off

United StatesWed Nov 18 2026

The bacteria behind gonorrhea keep learning how to beat the drugs sent to kill them. Right now, ceftriaxone stands as the only go-to shot for simple cases in the United States. That leaves doctors working with a thin safety net.

Ciprofloxacin lost its top spot long ago because the germ fought it off too often. Still, the pill costs little and clears infections that stay vulnerable to it. A lab check can point out exactly who fits that group.

Choosing the drug after the test result comes back is one approach being studied. It could mean fewer failed cures and fewer health problems down the road. It might also stop strong antibiotics from being burned up when they are not needed. On top of that, it could slow the germ and keep newer drugs working longer.

To weigh the money side, a team built a computer model that rolls the dice for each virtual patient. It tracked how common the infection is, who feels sick, how well tests perform, which drugs still work, the roads care takes, and how partners get handled. Every cost was set in 2025 dollars.

The model compared three testing plans. One relied only on ciprofloxacin, while another paired that pill with ceftriaxone. The researchers weighed savings today, delays in resistance, and the cost of making new antibiotics that could be skipped. Results like these can shape fair prices and coverage choices.

actions